Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Open-label sulfasalazine (alone or in combination with UDCA) has been reported to improve serum liver tests.210,211”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [210]
Citations
Cites
THE ROLE OF INTESTINAL BACTERIA IN THE METABOLISM OF SALICYLAZOSULFAPYRIDINE
PEPPERCORN, M. A., & GOLDMAN, P. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29238-2 · Cited by 450
Clinical Evidence Supporting the Radical Scavenger Mechanism of 5-Aminosalicylic Acid
Ahnfelt-Rønne, I., Nielsen, O. H., Christensen, A., Langholz, E., Binder, V., & Riis, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90329-y · Cited by 235
Bile acids for primary sclerosing cholangitis
Poropat, G., Giljaca, V., Stimac, D., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003626.pub2 · Cited by 95
Stevens, C., Lipman, M. L., Fabry, S., Moscovitch‐Lopatin, M., Almawi, W. Y., Keresztes, S., Peppercorn, M. A., & Strom, T. B. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24345-2 · Cited by 73
Glucocorticosteroids for primary sclerosing cholangitis
Giljača, V., Poropat, G., Štimac, D., & Gluud, C. N. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004036.pub3 · Cited by 44
Bile acids for primary sclerosing cholangitis
Chen, W., & Gluud, C. N. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003626 · Cited by 36
KOZAIWA, K., TAJIRI, H., SAWADA, A., TADA, K., ETANI, Y., MIKI, K., & OKADA, S. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1998.tb00740.x · Cited by 19
Glucocorticosteroids for primary sclerosing cholangitis
Chen, W., & Gluud, C. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004036.pub2 · Cited by 14
Research works printed but not linked: 2
- MA Peppercorn, 1972, J Pharmacol Exp Ther, 181, 555
- C Stevens, 1995, J Pharmacol Exp Ther, 272, 399
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Tabibian, J. H., Weeding, E., Jorgensen, R. A., Petz, J. L., Keach, J. C., Talwalkar, J. A., & Lindor, K. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12232 · Cited by 267
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247
The microbiota and the gut–liver axis in primary sclerosing cholangitis
Hov, J. R., & Karlsen, T. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00690-y · Cited by 141
Tabibian, J. H., O’Hara, S. P., & Lindor, K. D. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.913189 · Cited by 93
Primary sclerosing cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/824168 · Cited by 93
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
Tabibian, J. H., Talwalkar, J. A., & Lindor, K. D. (2013) · BioMed Research International · doi:10.1155/2013/389537 · Cited by 91
“Sulfasalazine [41] 2006 1 2–4.”
BackgroundShah, A., Crawford, D., Burger, D., Martin, N., Walker, M., Talley, N. J., Tallis, C., Jones, M., Stuart, K., Keely, S., et al. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1688501 · Cited by 81
The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
Hov, J., & Karlsen, T. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608801 · Cited by 65
Iwasawa, K., Suda, W., Tsunoda, T., Oikawa-Kawamoto, M., Umetsu, S., Takayasu, L., Inui, A., Fujisawa, T., Morita, H., Sogo, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23870-w · Cited by 60
Primary sclerosing cholangitis: a review and update on therapeutic developments
Tabibian, J. H., & Lindor, K. D. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.80 · Cited by 61
Pharmacological interventions for primary sclerosing cholangitis
Saffioti, F., Gurusamy, K. S., Hawkins, N., Toon, C. D., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011343.pub2 · Cited by 28
Current Therapeutics in Primary Sclerosing Cholangitis
Tan, N. P., Lubel, J. S., Kemp, W. W., Roberts, S. K., & Majeed, A. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00068s · Cited by 23
The medical management of primary sclerosing cholangitis.
Michaels, A. J., & Levy, C. (2008) · PubMed Central · Cited by 12
Autoimmune liver disease and the enteric microbiome
Glassner, K. L., Quigley, E. M. M., Franco, L., & Victor, D. W. (2018) · AIMS Microbiology · doi:10.3934/microbiol.2018.2.334 · Cited by 6
Chiba, M., Tsuda, H., Tsuda, S., Komatsu, M., Horie, Y., & Ohnishi, H. (2014) · Health · doi:10.4236/health.2014.610122 · Cited by 1
“reported that sulfasalazine was effective for PSC associated with UC [10].”
BackgroundPrimary Sclerosing Cholangitis
Silveira, M. G., & Lindor, K. D. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_50 · Cited by 1
Nakazawa, M., Nagase, Y., Igarashi, G., Fukuda, Y., Baba, S., Aida, Y., Miyawaki, M., & SUZUKI, M. T. (2007) · Kanzo · doi:10.2957/kanzo.48.446
Xu, J., Wang, X., Zhang, Y., Xiao, J., You, H., Liu, Z. Y., Sun, Y., Lan, Y. H., Ren, H., Liu, C.-G., et al. (2025) · PubMed Central · doi:10.3760/cma.j.cn501113-20250124-00041
Microbiome-Targeted Therapies for Primary Sclerosing Cholangitis
Carson, M., Meadows, V., & Nejak‐Bowen, K. N. (2026) · Seminars in Liver Disease · doi:10.1055/a-2983-7443
Metadata
- Authors
- Tada, S., Ebinuma, H., Saito, H., & Hibi, T.
- Affiliations
- Keio University (JP)
- Venue
- Journal of Gastroenterology
- Published
- 2006-06-02
- Volume
- 41
- Issue
- 4
- Pages
- 388-389
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2000693478
- Cited by
- 18
- References
- 8
- Citations by year
- 2023: 1 · 2022: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2014: 2 · 2013: 3
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- sulfasalazine, primary sclerosing cholangitis, therapeutic benefits, anti-inflammatory therapy, cholestatic liver disease
- MeSH terms
- Adolescent, Biopsy, Cholangiopancreatography, Endoscopic Retrograde, Gastrointestinal Agents, Humans, Liver, Male, Sulfasalazine, Cholangitis, Sclerosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.